Ann Marie Flores1, Kathleen Dwyer2. 1. Department of Physical Therapy, Rehabilitation and Movement Sciences, Center for Cancer Survivorship Studies, Northeastern University, Boston, MA. 2. College of Nursing, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117.
Abstract
OBJECTIVE: To compare pre- and post-operative shoulder active range of motion (AROM) values from female breast cancer survivors to population norm values for shoulder AROM; and to compare shoulder AROM differences pre- and post-surgery between female African American and White breast cancer survivors (BCA). STUDY DESIGN: This pilot study used a convenience sample and longitudinal design measuring participants 2 times (T0 = baseline, after biopsy but within 2 weeks before BCA surgery; T1 = 2nd postoperative week). BACKGROUND: The U.S. has the largest BCA survivor population in history and yet the mortality burden remains highest among AA BCA survivors. AAs may also have greater burden of physical and functional side effects compared to whites and the general population. METHODS AND MEASURES: The data were collected from a convenience sample (n = 33; nAA = 9, nW = 24) and included data on shoulder AROM, medical chart review for pre- and co-morbid conditions, and self-reported demographics and medical history. We used t-tests to compare sample AROM means to population norms. We then compared our sample across 2 timepoints (T0 = pre-surgery; T1 = 2 weeks post-surgery) using independent samples t-tests and repeated measures analysis of variance (p < .05) to compare AA to White sub-samples AROM means. RESULTS:African Americans had significantly less shoulder abduction (at T0) and flexion (at T1) than whites. However, 100% had significantly reduced AROM for all movements at T0 (prior to surgery but after biopsy) when compared to population norms. CONCLUSIONS: The significant reduction in shoulder AROM after biopsy but before surgery points to a possible unmet need for early physical therapy intervention. Further research using randomized controlled trial design is recommended.
RCT Entities:
OBJECTIVE: To compare pre- and post-operative shoulder active range of motion (AROM) values from female breast cancer survivors to population norm values for shoulder AROM; and to compare shoulder AROM differences pre- and post-surgery between female African American and White breast cancer survivors (BCA). STUDY DESIGN: This pilot study used a convenience sample and longitudinal design measuring participants 2 times (T0 = baseline, after biopsy but within 2 weeks before BCA surgery; T1 = 2nd postoperative week). BACKGROUND: The U.S. has the largest BCA survivor population in history and yet the mortality burden remains highest among AA BCA survivors. AAs may also have greater burden of physical and functional side effects compared to whites and the general population. METHODS AND MEASURES: The data were collected from a convenience sample (n = 33; nAA = 9, nW = 24) and included data on shoulder AROM, medical chart review for pre- and co-morbid conditions, and self-reported demographics and medical history. We used t-tests to compare sample AROM means to population norms. We then compared our sample across 2 timepoints (T0 = pre-surgery; T1 = 2 weeks post-surgery) using independent samples t-tests and repeated measures analysis of variance (p < .05) to compare AA to White sub-samples AROM means. RESULTS: African Americans had significantly less shoulder abduction (at T0) and flexion (at T1) than whites. However, 100% had significantly reduced AROM for all movements at T0 (prior to surgery but after biopsy) when compared to population norms. CONCLUSIONS: The significant reduction in shoulder AROM after biopsy but before surgery points to a possible unmet need for early physical therapy intervention. Further research using randomized controlled trial design is recommended.
Entities:
Keywords:
breast cancer; cancer survivorship; physical therapy; shoulder range of motion
Authors: T Kuehn; W Klauss; M Darsow; S Regele; F Flock; C Maiterth; R Dahlbender; I Wendt; R Kreienberg Journal: Breast Cancer Res Treat Date: 2000-12 Impact factor: 4.872
Authors: Mary E Sehl; William A Satariano; David R Ragland; David B Reuben; Arash Naeim Journal: Crit Rev Oncol Hematol Date: 2008-12-09 Impact factor: 6.312
Authors: C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya Journal: N Engl J Med Date: 1994-03-03 Impact factor: 91.245
Authors: Bette J Caan; Jennifer A Emond; Loki Natarajan; Adrienne Castillo; Erica P Gunderson; Laurel Habel; Lovell Jones; Vicky A Newman; Cheryl L Rock; Martha L Slattery; Marcia L Stefanick; Barbara Sternfeld; Cynthia A Thomson; John P Pierce Journal: Breast Cancer Res Treat Date: 2006-03-16 Impact factor: 4.872
Authors: Jennifer Baima; Sara-Grace Reynolds; Kathryn Edmiston; Anne Larkin; B Marie Ward; Ashling O'Connor Journal: J Cancer Educ Date: 2017-06 Impact factor: 2.037
Authors: Silvia Beatríz García-González; María Raquel Huerta-Franco; Israel Miguel-Andrés; José de Jesús Mayagoitia-Vázquez; Miguel León-Rodríguez; Karla Barrera-Beltrán; Gilberto Espinoza-Macías Journal: Healthcare (Basel) Date: 2022-04-11